Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00685815 · ClinicalTrials.gov registry record · Phase 2

Intravenous Iron Metabolism in Restless Legs Syndrome

A Phase 2 study, sponsored by American Regent.

Completed
Registry status
Phase 2
Development phase
12
Enrollment target

NCT00685815: Completed Phase 2 study, sponsored by American Regent.

NCT00685815 is a Phase 2 study that has completed, run by American Regent. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00685815, a Phase 2 study, has completed, sponsored by American Regent.

COMPLETED
Registry status
Phase 2
Development phase
12 participants
Enrollment target

Study Summary

Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome

Primary Outcome

Number of weeks that patients were able to remain off treatment for RLS

Interventions

  • DRUG Placebo
  • DRUG Ferric Carboxymaltose (FCM)

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2006-11
Est. Completion 2012-12
Phase Phase 2
American Regent

34 total trials

What the finished NCT00685815 record still lists

NCT00685815 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00685815 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00685815 about?

NCT00685815 is a clinical study titled "Intravenous Iron Metabolism in Restless Legs Syndrome". Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome

What is the current status of trial NCT00685815?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-11. Estimated completion is 2012-12.

What interventions are being tested in trial NCT00685815?

The interventions under investigation include: Placebo (DRUG), Ferric Carboxymaltose (FCM) (DRUG).

Who is sponsoring clinical trial NCT00685815?

This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00685815's enrollment target sits among peer trials

12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00685815, the US trial registry maintained by the National Library of Medicine. NCT00685815 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.